

116TH CONGRESS  
1ST SESSION

# H. R. 2011

To amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biologics license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009.

---

## IN THE HOUSE OF REPRESENTATIVES

APRIL 1, 2019

Ms. DEGETTE (for herself, Mr. REED, Ms. SCHRIER, and Mr. GUTHRIE) introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biologics license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Protecting Access to  
5 Biosimilars Act of 2019”.

1 **SEC. 2. TREATMENT OF BIOLOGICAL PRODUCTS DEEMED**  
 2 **LICENSED.**

3 Section 351(k)(7) of the Public Health Service Act  
 4 (42 U.S.C. 262(k)(7)) is amended by adding at the end  
 5 the following:

6 “(D) DEEMED LICENSES.—

7 “(i) NO ADDITIONAL EXCLUSIVITY  
 8 THROUGH DEEMING.—An approved appli-  
 9 cation that is deemed to be a license for a  
 10 biological product under this section pursu-  
 11 ant to section 7002(e)(4) of the Biologics  
 12 Price Competition and Innovation Act of  
 13 2009 shall not be treated as having been  
 14 first licensed under subsection (a) for pur-  
 15 poses of subparagraphs (A) and (B).

16 “(ii) APPLICABILITY OF  
 17 ANTIEVERGREENING PROVISIONS.—Sub-  
 18 paragraph (C) shall apply to any reference  
 19 product, without regard to whether—

20 “(I) such product was first li-  
 21 censed under subsection (a); or

22 “(II) the approved application for  
 23 such product was deemed to be a li-  
 24 cense for a biological product as de-  
 25 scribed in clause (i).”.